Cecolin®9, the world’s second HPV 9-valent vaccine, has received China’s Biological Products Batch Release Certificate from NIFDC in August, 2025,—officially launching in China and marking the start of its global journey.

On July 9th, at the "High-Level Meeting on Thailand's 2026 HPV Vaccination Program" hosted by Thai Department of Juvenile Observation & Protection (DJOP), Thai Ministry of Justice and the Thai Gynecologic Cancer Society (TGCS), INNOVAX participated as a key partner and, join hands with Global Biotech Products (GBP) in this program as a CSR program, announced a donation of special funding and bivalent HPV vaccine—Cecolin®, to support cervical cancer prevention efforts for Thai youth.

On June 5, 2025, the China National Intellectual Property Administration (CNIPA) announced the winners of the 25th China Patent Award.The invention patent "Truncated L1 Protein of Human Papillomavirus Type 16" (Patent No. ZL 200810093816.8), jointly held by Xiamen Innovax Biotech Co., Ltd. and Xiamen University, was honored with the China Patent Gold Award. The inventors of this Gold Award-winning patent are Gu Ying, Li Shaowei, Wei Minxi, Xian Yangling, Luo Wenxin, and Xia Ningshao.

Recently, the China National Medical Products Administration（NMPA) granted approval to a groundbreaking 9-valent HPV vaccine, Cecolin®9, jointly developed by Xiamen Innovax Biotech Co., Ltd and Xiamen University. This milestone makes China the second country in the world, after the United States, capable of independently manufacturing and supplying the 9-valent HPV vaccine.